| CaCO3@CoP |
4T1 breast cancer cells |
The synergy of CDT and calcium overload to maximize oxidative
damage and enhance cancer therapy |
(92) |
| CaCO3/Cu/Pt (oxali Platin) |
4T1 breast cancer
cells |
Neutralize TME; oxaliplatin is used for chemotherapy;
Cu2+ is used for CDT; the oxaliplatin and produced ROS
could
also induce the ICD of cancer cells |
(93) |
| CDDP/OA-LCC |
Hepatocellular carcinoma |
Co-delivery of CDDP and OA via a pH-sensitive CaCO3 drug
delivery system for enhanced tumor efficacy and reduced adverse
effects |
(24) |
| CPCa |
4T1 breast cancer cells |
Available for tumor targeting and imaging-guided PTT with synergistic
immunotherapy |
(71) |
| CaCO3/PDA-SA |
Melanoma |
Enhanced melanoma treatment by the synergistic
effect of PTT
and Ca2+ interference therapy |
(20) |
| LST-IR820-Ca |
Triple negative breast cancer |
Synergistic PTT/PDT therapy and exploitation of LST to reduce
solid stress of the tumor through depletion of collagen I |
(94) |
| CuS@Axitinib-SiO2@2-Deoxy-d-glucose(2-DG)-CaCO3-RGD |
4T1 breast cancer cells |
Achieve
severe tumor starvation and further enhance tumor treatment
with the aid of PTT, CDT, and TME improvement |
(95) |
| CaCO3-GEM-Triapine |
Pancreatic cancer |
Inhibition of cancer cell proliferation, migration and resistance
to GEM using 2D PANC-1/GEM cells and 3D tumor spheroids enhanced the
therapeutic efficacy of GEM-based chemotherapy. |
(96) |
| G/A@CaCO3-PEG |
Pancreatic cancer |
Increase heat-based tumor therapy
by limiting ATP availability |
(37) |
| IrCOOH-CaCO3@PEG |
4T1 breast cancer cells |
The combination of calcium overload and Ir complex irradiation
with the generation of ROS leads to tumor death |
(78) |
| CaNPs@Gel-MS |
Hepatocellular carcinoma |
Reverses lactate-induced chemotherapy resistance during TACE
treatment |
(97) |
| CaCO3@TCL/CpG |
Triple negative breast cancer |
Neutralize TME
and promote immunotherapy |
(66) |
| O2-FeCOF@CaCO3@FA |
4T1 breast cancer cells |
Establishment
of a mitochondrial pathway that inhibits tumor
growth and synergizes with PDA using dual-activated MPTP channels |
(98) |
| PGP/CaCO3@IR820/DTX-HA |
Castration-resistant
prostate cancer |
TME-activated synergistic PTT/PDT/chemical
therapy strategy |
(35) |
| IL-12 mRNA@cRGD-CM-CaCO3
|
Glioblastoma multiforme |
Cross the blood-brain barrier and cause necrotic prolapse-induced
immune responses and IL-12 mRNA transfection by ultrasound irradiation |
(62) |
| CaCO3@Cur@QTX125@HA |
Colorectal
cancer |
Specific inhibitory effects on colorectal cancer
growth |
(78,99) |
